Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The phosphaturic hormone Fibroblast Growth Factor 23 (FGF23) controls phosphate homeostasis by regulating renal expression of sodium-dependent phosphate co-transporters and cytochrome P450 enzymes involved in vitamin D catabolism. Multiple FGF Receptors (FGFRs) can act as receptors for FGF23 when bound by the co-receptor Klotho expressed in the renal tubular epithelium. FGFRs also regulate skeletal FGF23 secretion; ectopic FGFR activation is implicated in genetic conditions associated with FGF23 overproduction and hypophosphatemia. The identity of FGFRs that mediate the activity of FGF23 or that regulate skeletal FGF23 secretion remains ill defined. Here we report that pharmacological activation of FGFR1 with monoclonal anti-FGFR1 antibodies (R1MAb) in adult mice is sufficient to cause an elevation in serum FGF23 and mild hypophosphatemia. In cultured rat calvariae osteoblasts, R1MAb induces FGF23 mRNA expression and FGF23 protein secretion into the culture medium. In a cultured kidney epithelial cell line, R1MAb acts as a functional FGF23 mimetic and activates the FGF23 program. siRNA-mediated Fgfr1 knockdown induced the opposite effects. Taken together, our work reveals the central role of FGFR1 in the regulation of FGF23 production and signal transduction, and has implications in the pathogenesis of FGF23-related hypophosphatemic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945 · cited 1×
“FGFR1 plays important roles during embryonic development, in particular in skeletal development [29].”
BackgroundFeng, J. Q., Ward, L. M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S. I., Zhang, S., et al. (2006) · Nature Genetics · doi:10.1038/ng1905 · Cited by 1,199 · cited 1×
“In addition, inactivating mutations in genes such as dentin matrix acidic phosphoprotein 1 (Dmp1) [8], Phosphate regulating endopeptidase homolog, X-linked (Phex) [9], or Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1) [10,11], have been shown to increase skeletal secretion of FGF23, resulting in hypophosp…”
BackgroundDysregulation of the fibroblast growth factor system in major depression
Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., Lopez, J. F., Thompson, R. C., Meng, F., Stead, J. D., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406788101 · Cited by 424 · cited 1×
“Modulation of FGFR pathway has been implicated in major mood depressive and other psychiatric disorders [36,37].”
BackgroundBai, X., Miao, D., Li, J., Goltzman, D., & Karaplis, A. C. (2004) · Endocrinology · doi:10.1210/en.2004-0233 · Cited by 329 · cited 3×
“In a subsequent study, however, FGF23 did not reduce PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e57322 serum phosphorus levels in double Fgfr3/Fgfr4 KO mice [18], suggesting that FGFR3 and FGFR4 play redundant roles in phosphate regulation, and perhaps that FGFR1 activation is not sufficient for…”
BackgroundMartin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., & Quarles, L. D. (2011) · The FASEB Journal · doi:10.1096/fj.10-177816 · Cited by 254 · cited 2×
“In addition, FGF1 and FGF2 increased FGF23 promoter activity in a reporter assay in osteoblastic cells [19,20].”
Background
Cited by
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
Fibroblast growth factor signaling in skeletal development and disease
Ornitz, D. M., & Marie, P. J. (2015) · Genes & Development · doi:10.1101/gad.266551.115 · Cited by 418
Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli
Ito, N., Wijenayaka, A. R., Prideaux, M., Kogawa, M., Ormsby, R. T., Evdokiou, A., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.10.007 · Cited by 169
“…disorders imply that parathyroid hormone 1 receptor (PTH1R) and fibroblast growth hormone receptor 1 (FGFR1) signals are possible stimulants of FGF23 synthesis (Brown et al., 2009; Ito et al., 2014; Martin et al., 2011; Rhee et al., 2011; White et al., 2005; Wohrle et al., 2011; Wu et al., 2013).”
Kolumam, G., Chen, M. Z., Tong, R., Zavala-Solorio, J., Kates, L., van Bruggen, N., Ross, J., Wyatt, S. K., Gandham, V. D., Carano, R. A. D., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.05.028 · Cited by 108
“In addition, unlike anti-FGFR1 R1MAb1 that alters the levels of serum FGF23 and phosphorus by activating FGFR1 in bone and kidney (Wu et al., 2011a, 2013), bFKB1 did not affect these serum parameters, indicating the absence of KLB-independent FGFR1 agonism or antagonism (Fig.”
BackgroundSelf-citation
Metadata
- Authors
- Wu, A.-L., Feng, B., Chen, M. Z., Kolumam, G., Zavala-Solorio, J., Wyatt, S. K., Gandham, V. D., Carano, R. A. D., & Sonoda, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-02-22
- Volume
- 8
- Issue
- 2
- Pages
- e57322
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2170025614
- Cited by
- 67
- References
- 5
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.